Breastfeeding and Overweight in European Preschoolers: The ToyBox Study

Natalya Usheva1, Mina Lateva2, Sonya Galcheva2

  • 1Department of Social Medicine and Health Care Organization, Medical University of Varna, 9002 Varna, Bulgaria.

Nutrients
|August 27, 2021
PubMed

Insights

Breastfeeding offers health benefits, but this study found no direct link to reduced childhood obesity. Sociodemographic and lifestyle factors may play a larger role in childhood overweight and obesity.

Area of Science:

  • Pediatrics
  • Public Health
  • Nutrition

Background:

  • Breastfeeding (BF) is associated with reduced risk of later overweight and obesity.
  • Understanding the relationship between infant feeding practices and childhood obesity is crucial for public health interventions.

Purpose of the Study:

  • To analyze the association between breastfeeding practices and overweight/obesity in preschool children.
  • To identify factors influencing exclusive breastfeeding duration.

Main Methods:

  • Cross-sectional study of 7554 children aged 3.5-5.5 years across six European countries.
  • Data collected via parent questionnaires and objective measurements of children's weight and height.
  • Statistical analysis adjusted for confounding sociodemographic and lifestyle factors.

Main Results:

  • The overall breastfeeding rate was 85.0%, with only 6.3% exclusively breastfed for six months.
  • Exclusive breastfeeding was less likely among mothers with lower education, smoking during pregnancy, pre-pregnancy overweight, or younger age.
  • No significant association was found between breastfeeding practices and childhood overweight or obesity after adjusting for confounders.

Conclusions:

  • Sociodemographic and lifestyle factors, rather than breastfeeding practices alone, may significantly influence childhood obesity.
  • Lower-than-desirable breastfeeding rates and durations necessitate enhanced promotion, protection, and support for breastfeeding in Europe.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
741
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
30
Regression Toward the Mean01:52

Regression Toward the Mean

Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when...
6.6K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
55
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
30
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
30